- Home
- FDMT vs GUG Comparison
FDMT vs GUG Comparison
Compare FDMT & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FDMT | GUG |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 513.6M | 518.8M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FDMT | GUG |
|---|---|---|
| Price | $8.35 | $15.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.40 | N/A |
| AVG Volume (30 Days) | ★ 674.7K | 58.1K |
| Earning Date | 04-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,000.00 | N/A |
| Revenue This Year | $21,227.03 | N/A |
| Revenue Next Year | $161.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $13.90 |
| 52 Week High | $12.34 | $16.50 |
Technical Indicators
Market Signals| Indicator | FDMT | GUG |
|---|---|---|
| Relative Strength Index (RSI) | 42.07 | 30.74 |
| Support Level | $8.15 | $15.09 |
| Resistance Level | $8.80 | $15.73 |
| Average True Range (ATR) | 0.55 | 0.17 |
| MACD | -0.12 | -0.08 |
| Stochastic Oscillator | 7.86 | 2.94 |
Price Performance
Historical ComparisonAbout FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.